Fungal Hepatic Abscesses: Characterization and Management

Pamela A Lipsett, Chih Jen Huang, Keith D. Lillemoe, John L Cameron, Henry A. Pitt

Research output: Contribution to journalArticle

Abstract

Hepatic abscesses are being recognized with increasing frequency in immunocompromised patients and those with malignant diseases. Risk factors and treatment for patients with pure fungal abscesses and mixed fungal and pyogenic abscesses have not been well described. A retrospective review of patients with hepatic abscesses was undertaken at The Johns Hopkins Hospital from 1973 through 1993. Eight patients with pure fungal hepatic abscesses and 34 patients with mixed fungal/pyogenic abscesses were identified. Clinical presentation, diagnosis, management, and outcome were analyzed. In the group with pure fungal abscesses, fungemia was predictive of death; four patients in this group died, whereas the remaining four patients who received amphotericin B treatment before the onset of fungemia all survived. In the group with mixed fungal/pyogenic abscesses, 11 patients received amphotericin B, whereas 23 did not. Ten (43%) of these 23 patients died. However, only one of five patients who received more than 1000 mg of amphotericin B died. In patients with hematologic malignancies, who are known to be at risk for fungal infections, amphotericin B treatment should be instituted early. In patients with mixed fungal/pyogenic hepatic abscesses who fail to improve after drainage and broad-spectrum antibiotics, antimycotic therapy should be considered early, before the onset of fungemia.

Original languageEnglish (US)
Pages (from-to)78-84
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume1
Issue number1
StatePublished - Jan 1997

Fingerprint

Liver Abscess
Abscess
Amphotericin B
Fungemia
Pyogenic Liver Abscess
Mycoses
Immunocompromised Host
Hematologic Neoplasms
Therapeutics
Drainage

ASJC Scopus subject areas

  • Surgery

Cite this

Fungal Hepatic Abscesses : Characterization and Management. / Lipsett, Pamela A; Huang, Chih Jen; Lillemoe, Keith D.; Cameron, John L; Pitt, Henry A.

In: Journal of Gastrointestinal Surgery, Vol. 1, No. 1, 01.1997, p. 78-84.

Research output: Contribution to journalArticle

Lipsett, Pamela A ; Huang, Chih Jen ; Lillemoe, Keith D. ; Cameron, John L ; Pitt, Henry A. / Fungal Hepatic Abscesses : Characterization and Management. In: Journal of Gastrointestinal Surgery. 1997 ; Vol. 1, No. 1. pp. 78-84.
@article{761ecd8058c248c79c589a05efec475a,
title = "Fungal Hepatic Abscesses: Characterization and Management",
abstract = "Hepatic abscesses are being recognized with increasing frequency in immunocompromised patients and those with malignant diseases. Risk factors and treatment for patients with pure fungal abscesses and mixed fungal and pyogenic abscesses have not been well described. A retrospective review of patients with hepatic abscesses was undertaken at The Johns Hopkins Hospital from 1973 through 1993. Eight patients with pure fungal hepatic abscesses and 34 patients with mixed fungal/pyogenic abscesses were identified. Clinical presentation, diagnosis, management, and outcome were analyzed. In the group with pure fungal abscesses, fungemia was predictive of death; four patients in this group died, whereas the remaining four patients who received amphotericin B treatment before the onset of fungemia all survived. In the group with mixed fungal/pyogenic abscesses, 11 patients received amphotericin B, whereas 23 did not. Ten (43{\%}) of these 23 patients died. However, only one of five patients who received more than 1000 mg of amphotericin B died. In patients with hematologic malignancies, who are known to be at risk for fungal infections, amphotericin B treatment should be instituted early. In patients with mixed fungal/pyogenic hepatic abscesses who fail to improve after drainage and broad-spectrum antibiotics, antimycotic therapy should be considered early, before the onset of fungemia.",
author = "Lipsett, {Pamela A} and Huang, {Chih Jen} and Lillemoe, {Keith D.} and Cameron, {John L} and Pitt, {Henry A.}",
year = "1997",
month = "1",
language = "English (US)",
volume = "1",
pages = "78--84",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Fungal Hepatic Abscesses

T2 - Characterization and Management

AU - Lipsett, Pamela A

AU - Huang, Chih Jen

AU - Lillemoe, Keith D.

AU - Cameron, John L

AU - Pitt, Henry A.

PY - 1997/1

Y1 - 1997/1

N2 - Hepatic abscesses are being recognized with increasing frequency in immunocompromised patients and those with malignant diseases. Risk factors and treatment for patients with pure fungal abscesses and mixed fungal and pyogenic abscesses have not been well described. A retrospective review of patients with hepatic abscesses was undertaken at The Johns Hopkins Hospital from 1973 through 1993. Eight patients with pure fungal hepatic abscesses and 34 patients with mixed fungal/pyogenic abscesses were identified. Clinical presentation, diagnosis, management, and outcome were analyzed. In the group with pure fungal abscesses, fungemia was predictive of death; four patients in this group died, whereas the remaining four patients who received amphotericin B treatment before the onset of fungemia all survived. In the group with mixed fungal/pyogenic abscesses, 11 patients received amphotericin B, whereas 23 did not. Ten (43%) of these 23 patients died. However, only one of five patients who received more than 1000 mg of amphotericin B died. In patients with hematologic malignancies, who are known to be at risk for fungal infections, amphotericin B treatment should be instituted early. In patients with mixed fungal/pyogenic hepatic abscesses who fail to improve after drainage and broad-spectrum antibiotics, antimycotic therapy should be considered early, before the onset of fungemia.

AB - Hepatic abscesses are being recognized with increasing frequency in immunocompromised patients and those with malignant diseases. Risk factors and treatment for patients with pure fungal abscesses and mixed fungal and pyogenic abscesses have not been well described. A retrospective review of patients with hepatic abscesses was undertaken at The Johns Hopkins Hospital from 1973 through 1993. Eight patients with pure fungal hepatic abscesses and 34 patients with mixed fungal/pyogenic abscesses were identified. Clinical presentation, diagnosis, management, and outcome were analyzed. In the group with pure fungal abscesses, fungemia was predictive of death; four patients in this group died, whereas the remaining four patients who received amphotericin B treatment before the onset of fungemia all survived. In the group with mixed fungal/pyogenic abscesses, 11 patients received amphotericin B, whereas 23 did not. Ten (43%) of these 23 patients died. However, only one of five patients who received more than 1000 mg of amphotericin B died. In patients with hematologic malignancies, who are known to be at risk for fungal infections, amphotericin B treatment should be instituted early. In patients with mixed fungal/pyogenic hepatic abscesses who fail to improve after drainage and broad-spectrum antibiotics, antimycotic therapy should be considered early, before the onset of fungemia.

UR - http://www.scopus.com/inward/record.url?scp=0347771686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347771686&partnerID=8YFLogxK

M3 - Article

C2 - 9834333

AN - SCOPUS:0347771686

VL - 1

SP - 78

EP - 84

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 1

ER -